Genmab A/S (GMAB) Stock Price & Analysis

GMAB$50.60-0.75 -1.46%
BiotechnologyLarge CapHigh Quality
Compare
Market cap$31.20BEnterprise value$34.54BRevenue (TTM)$4.3BMarket positionTop 25%

Score

37
Bearish
Value
29
Quality
63
Growth
20

AI Analysis

Snapshot

Genmab A/S doesn’t screen as a clean setup today — Stocklytics 37/100 leaves more to prove. Under the hood: P/E 42.8, plus revenue compounding ~-13% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

29
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

20
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

63
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Genmab A/S (GMAB) last printed $50.60. Equity value is $31.20B. Trailing earnings multiple 42.52. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$1.82B$2.37B$3.03B$5.37B$10.11B$8.42B$14.51B$16.47B$21.53B$3.72B

About

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Genmab A/S (GMAB) Stock Price & Analysis

GMAB price $50.60 -0.75 -1.46%

Ticker
GMAB
Price
$50.60
Change
-0.75 -1.46%
Market cap
$31.20B
P/E
42.52
Forward P/E
40.20
Dividend yield
0.00%
Beta
0.65
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
37
Value
29
Quality
63
Growth
20

Stocklytics score rationale: value 29, quality 63, growth 20.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener